SCHEMBL27374101

SCHEMBL27374101

Cc1nc2ccccc2c(N)c1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.62
TP53 P04637 2/20 0.62
ALDH1A1 P00352 5/20 0.58
HPGD P15428 4/20 0.58
CYP1A2 P05177 3/20 0.58
NUDT1 P36639 1/20 0.58
KDM4E B2RXH2 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
GLA P06280 2/20 0.57
CASP1 P29466 2/20 0.57
CASP7 P55210 2/20 0.57
ACHE P22303 2/20 0.57
CHRM2 P08172 1/20 0.57
ADRA2A P08913 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CHRM1 P11229 1/20 0.57
NQO2 P16083 1/20 0.57
MAOA P21397 1/20 0.57
DRD1 P21728 1/20 0.57
SLC6A2 P23975 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL440157 0.82 ALDH1A1 (0.64) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL30025532 0.82 ALDH1A1 (0.64) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL27296318 0.82 ALDH1A1 (0.64) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL25049845 0.80 ERN1 (0.61) HSD17B10TP53ALDH1A1HPGDCYP1A2
Aminacrine SCHEMBL11419528 0.77 ALDH1A1 (0.86) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL3892400 0.77 ERN1 (0.57) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL7522141 0.77 ERN1 (0.57) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL6784629 0.77 ERN1 (0.57) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL28220555 0.77 ALDH1A1 (0.58) HSD17B10TP53ALDH1A1HPGDCYP1A2
SCHEMBL27886134 0.77 ERN1 (0.57) HSD17B10TP53ALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024105553-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS NOVARTIS AG (CH) 2024-05-23 WO disclosed